Metabolon is a leading provider of metabolomics research and development capabilities, providing many of the most well-known pharma, academic, and consumer institutions with critical and actionable information on the small molecules involved in metabolism that they cannot obtain from any other company today.

Metabolon is a leader in the metabolomics field, namely the systematic measurement and biological interpretation of the low molecular weight (~50-1500 Da) metabolites within a biological sample. Metabolon is a commercial-stage metabolomics company pioneering biomarker discovery and the development of innovative, cost-effective diagnostic tests.

Metabolon was founded in 2000 and maintains a 40,000 square foot headquarters and CLIA-certified, CAP-accredited lab in Research Triangle Park, North Carolina. The privately-held company employs ~150 people globally, with experts in the fields of biochemistry, mass spectrometry, and software development, and has conducted more than 4,000 studies across various therapeutic areas, 500+ of which have resulted in publications in leading journals such as Nature, Cell, Science, and JCI.

Transaction Summary

  • Dr. Tom Caskey, Senior Advisor to EW Healthcare Partners (EW), was previously a member of Metabolon's Board, and has closely followed Metabolon's scientific and commercial progress.
  • Scott Barry engaged with Metabolon in late 2015 and after several months of diligence and building relationships with the company's management team and existing investors, EW made an investment to help further accelerate the company's growth.
  • In 2016, EW invested $15 million in primary capital to accelerate the growth of Metabolon's services and precision medicine businesses. An additional $15 million was invested to repurchase shares from existing investors, making EW the largest investor.
  • EW's capital will drive continued growth of the core metabolomics services business while enabling investments in the development and commercialization of proprietary diagnostics in diabetes, kidney disease, and precision medicine based on Metabolon's technology.
  • This investment was a proprietary transaction, sourced by EW's industry networks without any intermediaries.